Search
Madrigal Pharmaceuticals Inc
MDGLAdd to Watchlist
505.750USD
+5.890+1.18%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
11.66BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Madrigal Pharmaceuticals Inc is 8.12, ranking 162 out of 389 in the Biotechnology & Medical Research industry. The average price target is 557.00, with a high of 650.00 and a low of 456.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
678.800
Target Price
+34.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Madrigal Pharmaceuticals Inc
MDGL
17
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Madrigal Pharmaceuticals Inc's expected revenue for the next quarter?
Madrigal Pharmaceuticals Inc's expected revenue is 350.14M.
What is Madrigal Pharmaceuticals Inc's price target?
Analysts forecast that Madrigal Pharmaceuticals Inc's price target is USD 557.00, with the highest forecast at USD 650.00 and the lowest forecast at USD 456.00.
How have Madrigal Pharmaceuticals IncMDGL's recent earnings per share performed?
The market expectation was USD -3.25, while Madrigal Pharmaceuticals IncMDGL's earnings per share (EPS) for the previous quarter was USD -2.55. EPS for the next quarter is expected at USD -2.34.
What is the analyst rating for Madrigal Pharmaceuticals Inc?
Based on the ratings of Madrigal Pharmaceuticals Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
